Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-04 4:30 pm Unchanged | 2026-05-15 | 13D | CITIUS ONCOLOGY INC CTOR | Citius Pharmaceuticals, Inc. CTXR | 66,049,615 71.000% | 0 (Unchanged) | Filing History |
| 2026-02-17 2:47 pm Purchase | 2025-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | CVI Investments, Inc. | 2,394,725 9.900% | 739,044 (+44.64%) | Filing History |
| 2025-12-17 4:10 pm Unchanged | 2025-12-10 | 13D | CITIUS ONCOLOGY INC CTOR | Citius Pharmaceuticals, Inc. CTXR | 66,049,615 77.900% | 0 (Unchanged) | Filing History |
| 2025-10-27 10:47 am Purchase | 2025-10-20 | 13G | CITIUS PHARMACEUTICALS INC CTXR | CVI Investments, Inc. | 1,655,681 9.900% | 1,655,681 (New Position) | Filing History |
| 2025-09-12 4:15 pm Unchanged | 2025-09-10 | 13D | CITIUS ONCOLOGY INC CTOR | Citius Pharmaceuticals, Inc. CTXR | 66,049,615 79.100% | 0 (Unchanged) | Filing History |
| 2025-07-25 5:00 pm Unchanged | 2025-07-17 | 13D | CITIUS ONCOLOGY INC CTOR | Citius Pharmaceuticals, Inc. CTXR | 66,049,615 84.300% | 0 (Unchanged) | Filing History |
| 2024-11-27 4:05 pm Sale | 2024-11-25 | 13D | CITIUS PHARMACEUTICALS INC CTXR | Mazur Leonard L | 754,295 9.300% | -17,337,841 (-95.83%) | Filing History |
| 2024-08-16 4:34 pm Purchase | 2024-08-12 | 13D | CITIUS ONCOLOGY INC CTOR | Citius Pharmaceuticals, Inc. CTXR | 66,049,615 92.600% | 66,049,615 (New Position) | Filing History |
| 2024-05-08 2:22 pm Purchase | 2024-04-30 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,625,839 4.800% | 168,025 (+1.99%) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,457,814 5.300% | 6,110,522 (+260.32%) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 2,347,292 1.600% | -5,780,964 (-71.12%) | Filing History |
| 2022-02-18 4:31 pm Purchase | 2019-04-03 | 13D | CITIUS PHARMACEUTICALS INC CTXR | Mazur Leonard L | 18,092,136 11.760% | 7,017,963 (+63.37%) | Filing History |
| 2022-02-18 4:30 pm Purchase | 2019-04-03 | 13D | CITIUS PHARMACEUTICALS INC CTXR | HOLUBIAK MYRON Z | 3,864,604 2.610% | 1,715,368 (+79.81%) | Filing History |
| 2022-02-14 6:44 pm Sale | 2021-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | Armistice Capital, LLC | 2,425,000 1.600% | -3,743,361 (-60.69%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,128,256 5.600% | 8,128,256 (New Position) | Filing History |